3-氨基吡啶-2-羧酸 | 1462-86-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基吡啶-2-羧酸
• 中文别名: 3-氨基吡啶-2-甲酸；3-氨基-2-羧酸吡啶；3-氨基-2-吡啶甲酸
• 英文名称: 3-amino-pyridine-2-carboxylic acid
• 英文别名: 3-aminopicolinic acid；3-amino-2-pyridinecarboxylic acid；3-aminopyridine-2-carboxylic acid
• CAS: 1462-86-8
• 化学式: C₆H₆N₂O₂
• mdl: MFCD00090153
• 分子量: 138.126
• InChiKey: BOOMHTFCWOJWFO-UHFFFAOYSA-N

物化性质

• 熔点：
  218-220
• 沸点：
  386.6±27.0 °C(Predicted)
• 密度：
  1.417±0.06 g/cm3(Predicted)
• 溶解度：
  易溶于丙酮、乙醇和甲醇。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37,S60
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• RTECS号：
  US5175000
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C freezer

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Aminopicolinic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Aminopicolinic acid
Ingredient name:
CAS number: 1462-86-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H6N2O2
Molecular weight: 138.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

性质

3-氨基吡啶-2-羧酸（3-Amino-2-pyridinecarboxylic acid），又称3-氨基-2-羧基吡啶、3-氨基-2-吡啶甲酸，分子式为C₆H₆N₂O₂，分子量138.12，CAS号1462-86-8。该化合物在室温下为固体，熔点为218-220 ℃，能溶于丙酮、乙醇和甲醇。

用途

3-氨基吡啶-2-羧酸主要用于制备哌啶基甲基嘌呤胺作为NSD2抑制剂和抗癌药物。

应用举例 医药合成

3-氨基吡啶-2-羧酸广泛应用于医药合成领域：

1. 合成3-巯基吡啶2-甲酸：研究发现含有n-吡啶羧酸结构的化合物具有良好的抑制糖异生的作用，其中3-巯基吡啶2-甲酸（4）是一种有效的降低血糖试剂。

2. 合成稠环4-氧代-嘧啶衍生物：日本万有制药株式会社采用3-氨基吡啶-2-羧酸、乙酸酐和4-(3-哌啶-1-基丙氧基)苯胺·一(甲苯磺酸)盐作为原料，合成了特定的稠环4-氧代-嘧啶衍生物。这类化合物可作为组胺H₃受体拮抗剂或反向激动剂，发挥控制神经递质释放的作用。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-硝基吡啶-2-甲酸	3-Nitro-picolinsaeure	59290-85-6	C6H4N2O4	168.109

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  3-氨基吡啶-2-羧酸甲酯	methyl 3-aminopicolinate	36052-27-4	C7H8N2O2	152.153
  3-氨基吡啶-2-甲酸乙酯	ethyl 3-aminopyridine-2-carboxylate	27507-15-9	C8H10N2O2	166.18
  3-氨基-6-溴-2-吡啶羧酸	3-amino-6-bromopicolinic acid	1052708-46-9	C6H5BrN2O2	217.022
  3-氨基-2-羟甲基吡啶	3-amino-2-hydroxy-methylpyridine	52378-63-9	C6H8N2O	124.142
  3-[(1E)-3,3-二甲基-1-三氮烯-1-基]-2-吡啶羧酸	3-(3,3-dimethyltriazen-1-yl)pyridine-2-carboxylic acid	116708-30-6	C8H10N4O2	194.193
  3-氨基-6-溴吡啶-2-羧酸甲酯	methyl 3-amino-6-bromopicolinate	866775-09-9	C7H7BrN2O2	231.049
  ——	3-((carboxymethyl)amino)picolinic acid	7579-21-7	C8H8N2O4	196.163
  ——	3-benzylaminopicolinic acid	30687-72-0	C13H12N2O2	228.25
  3-氨基-6-溴吡啶-2-羧酸乙酯	ethyl 3-amino-6-bromopicolinate	28033-08-1	C8H9BrN2O2	245.076
  3-(Boc-氨基)吡啶-2-甲酸	3-tert-butoxycarbonylaminopyridine-2-carboxylic acid	569687-82-7	C11H14N2O4	238.243

反应信息

• 作为反应物：
  描述：

  3-氨基吡啶-2-羧酸 在 二甲基十二/十四烷基叔胺 、 硫酸 、 三氟乙酸酐 作用下， 以 异丁醇 、 水 、 乙酸乙酯 为溶剂， 生成 司来利塞
  参考文献：
  名称：

  [EN] CRYSTALLINE FORMS OF SELETALISIB
  [FR] FORMES CRISTALLINES DE SÉLÉTALISIB

  摘要：

  晶态形式的塞来替利西布，被指定为B型和F型，并在此处进行表征，作为选择性PI3激酶酶抑制剂，特别是人类ΡΒΚδ亚型，因此在医学上具有益处，例如在治疗炎症、自身免疫、心血管、神经退行性、代谢、肿瘤、疼痛或眼科疾病方面。

  公开号：

  WO2018219772A1
• 作为产物：
  描述：

  2,3-吡啶二酰亚胺 在 sodium hydroxide 、 sodium hypobromide 作用下， 反应 2.0h， 以10%的产率得到3-氨基吡啶-2-羧酸
  参考文献：
  名称：

  3-芳基-4-羟基喹啉-2（1H）-作为NMDA /甘氨酸部位拮抗剂的5-，6-，7-和8-氮杂类似物的合成和SAR。

  摘要：

  合成了3-芳基-4-羟基喹啉-2（1H）-one的一系列5-，6-，7-和8-氮杂类似物，并测定为NMDA /甘氨酸受体拮抗剂。这些拮抗剂的体外效能是通过在大鼠大脑皮膜中置换甘氨酸位点放射性配体[[（3）H] 5,7-dicholorokynurenic酸（[（3）H] DCKA）确定的。还使用表达克隆的NMDA受体（NR）1A / 2C亚基的非洲爪蟾卵母细胞中的电生理测定法测试了所选化合物的功能拮抗作用。在研究的5、6、7、8氮杂-3-芳基-4-羟基喹啉2（1H）-中，5-氮杂7-氯-4-羟基-3-（3-苯氧基苯基） ）quinolin-2-（1H）-one（13i）是最有效的拮抗剂，在[（3）H] DCKA结合中的IC（50）值为110 nM，在电生理学中的K（b）为11 nM分析。

  DOI：

  10.1016/s0968-0896(01)00115-8

文献信息

• Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods
  申请人：PathoGenesis Corporation

  公开号：US05441955A1

  公开（公告）日：1995-08-15

  Methods, compounds and compositions are provided form inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic mycobacterial infections in vivo using indolo[2,1-b]quinazoline-6,12-dione compounds of the formula (I): ##STR1## wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, and may be used alone, or in combination with other anti-Mycobacterium tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, rifabutin, streptomycin and ciprofloxacin, to provide new agents for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDRTB).

  提供了一种用于体外抑制病原性分枝杆菌生长和用于体内治疗病原性分枝杆菌感染的方法、化合物和组合物，使用式(I)的吲哚并[2,1-b]喹唑啉-6,12-二酮化合物：##STR1## 其中A、B、C、D、E、F、G和H独立地选自碳和氮，或A和B或C和D可以结合在一起成为氮或硫，并且其药学上可接受的盐。这些方法、化合物和组合物特别适用于抑制结核分枝杆菌的生长，并可单独使用，或与其他抗结核分枝杆菌药物（如异烟肼、利福平、吡嗪酰胺、利福布汀、链霉素和环丙沙星）结合使用，以提供用于治疗结核病的新药物，包括多药耐药结核病（MDRTB）。
• [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
  申请人：SANKYO CO

  公开号：WO2003106435A1

  公开（公告）日：2003-12-24

  AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

  新化合物具有以下式（I）的结构，其药学上可接受的盐和酯可以调节LXR功能，从而表现出优秀的抗动脉粥样硬化和抗炎活性：其中：A代表芳基或杂环芳基；R1、R2和R3相同或不同，每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-（烷基羰基）-N-（烷基）氨基、烷氧羰基氨基、N-（烷氧羰基）-N-（烷基）氨基、烷磺酰氨基、N-（烷磺酰基）-N-（烷基）氨基、卤代烷基磺酰氨基、N-（卤代烷基磺酰基）-N-（烷基）氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基，或R1和R2一起是亚烷二氧基；R4和R5相同或不同，每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基；X代表氢、羟基、卤素、烷氧基或卤代烷氧基；Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
• ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
  申请人：Centre National de la Recherche Scientifique

  公开号：US20210009581A1

  公开（公告）日：2021-01-14

  The present invention concerns a compound of following general formula (I): where: either R is an R 1 group and R′ is an -A 1 -Cy 1 group, or R is an -A 1 -Cy 1 group and R′ is an R 1 group, R 1 particularly being H or (C 1 -C 6 )alkyl group; A 1 being an —NH— radical or —NH—CH 2 — radical; Cy 1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

  本发明涉及以下一般式（I）的化合物： 其中： R是R1基团且R′是-A1-Cy1基团，或者R是-A1-Cy1基团且R′是R1基团， 其中R1特别是H或（C1-C6）烷基基团； A1是—NH—基团或—NH—CH2—基团； Cy1特别是苯基， A是具有5到7个原子的融合（杂）芳香环， 用于治疗癌症。
• 一种双乙烯磺酰胺连接子及其制备和应用
  申请人：上海科技大学

  公开号：CN107400072B

  公开（公告）日：2021-02-05

  本发明提供了一种双乙烯磺酰胺连接子及其制备和应用。所述的双乙烯磺酰胺连接子的结构式为式I或式II。本发明提供的新型双乙烯磺酰胺连接子不仅一端可以偶联多肽或蛋白，另一端同时可以连接亲和标记物或示踪荧光物质或活性药物。
• [EN] THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD<br/>[FR] COMPOSES THERAPEUTIQUES DANS LESQUELS LA PYRIDINE EST UTILISEE COMME SQUELETTE
  申请人：ASTRAZENECA AB

  公开号：WO2005115986A1

  公开（公告）日：2005-12-08

  Compounds of formulas I, IA, and IB or IC or pharmaceutically acceptable salts thereof: wherein A, A1, A2, A3, A4, R2, R3, R4 and n are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  其中A、A1、A2、A3、A4、R2、R3、R4和n的化合物的公式I、IA和IB或IC或其药学上可接受的盐：其中A、A1、A2、A3、A4、R2、R3、R4和n的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。